Stock CLPT CLEARPOINT NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
6.21 USD +2.48% Intraday chart for ClearPoint Neuro, Inc. -2.97% -8.54%
May. 07 ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CLS focuses on the Neurosurgery business area to optimize capital allocation, secure profitability targets and implement associated cost savings
AQ
ClearPoint Neuro Reports First Quarter 2024 Results
AQ
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PR
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators
AQ
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System
AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
AQ
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
AQ
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency
AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
AQ
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
AQ
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
AQ
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLPT Stock
  4. News ClearPoint Neuro, Inc.
  5. Press Releases